BR112022000064A2 - Inibidores de hpk1 e usos dos mesmos - Google Patents

Inibidores de hpk1 e usos dos mesmos

Info

Publication number
BR112022000064A2
BR112022000064A2 BR112022000064A BR112022000064A BR112022000064A2 BR 112022000064 A2 BR112022000064 A2 BR 112022000064A2 BR 112022000064 A BR112022000064 A BR 112022000064A BR 112022000064 A BR112022000064 A BR 112022000064A BR 112022000064 A2 BR112022000064 A2 BR 112022000064A2
Authority
BR
Brazil
Prior art keywords
hpk1
hpk1 inhibitors
inhibitors
formula
treatable
Prior art date
Application number
BR112022000064A
Other languages
English (en)
Inventor
Hao Liu
Hua Zhou
Xin Wen Kate
Lei Wu
Rongqiang Liu
Song Feng
Wei Huang
Wenge Zhong
Xiaotian Zhu
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of BR112022000064A2 publication Critical patent/BR112022000064A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

inibidores hpk1 e seus usos. a presente invenção refere-se a um composto representado pela fórmula estrutural (i-0) ou fórmula (ii): ou um sal farmaceuticamente aceitável ou um seu estereoisômero útil para o tratamento de doenças (tais como câncer) que são tratáveis pela inibição da atividade de hpk1.
BR112022000064A 2019-07-04 2020-07-03 Inibidores de hpk1 e usos dos mesmos BR112022000064A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019094634 2019-07-04
PCT/CN2020/100134 WO2021000935A1 (en) 2019-07-04 2020-07-03 Hpk1 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112022000064A2 true BR112022000064A2 (pt) 2022-05-24

Family

ID=74100919

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000064A BR112022000064A2 (pt) 2019-07-04 2020-07-03 Inibidores de hpk1 e usos dos mesmos

Country Status (13)

Country Link
US (2) US20220389037A1 (pt)
EP (2) EP3994133A4 (pt)
JP (2) JP2022538923A (pt)
KR (2) KR20220044495A (pt)
CN (2) CN114555585A (pt)
AU (2) AU2020298649A1 (pt)
BR (1) BR112022000064A2 (pt)
CA (1) CA3145973A1 (pt)
IL (1) IL289612A (pt)
MA (1) MA56462A (pt)
MX (2) MX2022000271A (pt)
TW (1) TW202116751A (pt)
WO (2) WO2021000935A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
AU2020298649A1 (en) * 2019-07-04 2022-02-17 Regor Pharmaceuticals, Inc. HPK1 inhibitors and uses thereof
CN116456985A (zh) * 2020-09-23 2023-07-18 深圳市原力生命科学有限公司 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法
CN116731046A (zh) * 2020-10-28 2023-09-12 杭州阿诺生物医药科技有限公司 一种高活性的hpk1激酶抑制剂
EP4305041A1 (en) * 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022214008A1 (zh) * 2021-04-08 2022-10-13 杭州阿诺生物医药科技有限公司 高活性hpk1激酶抑制剂
AU2022312496A1 (en) * 2021-07-14 2024-02-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
CN117693503A (zh) 2021-07-20 2024-03-12 阿斯利康(瑞典)有限公司 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
WO2023083299A1 (zh) * 2021-11-12 2023-05-19 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023134608A1 (zh) * 2022-01-11 2023-07-20 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023245329A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multi-kinase inhibitors, compositions thereof, and methods of using the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2008003766A2 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
EP3096754B1 (en) * 2014-01-22 2018-08-29 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
ES2837157T3 (es) * 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
WO2018049214A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MA46942A (fr) * 2016-11-30 2021-05-05 Ariad Pharma Inc Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1)
WO2018152220A1 (en) * 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
US11299493B2 (en) * 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US10745388B2 (en) * 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10899755B2 (en) * 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020235902A1 (ko) * 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
AU2020298649A1 (en) * 2019-07-04 2022-02-17 Regor Pharmaceuticals, Inc. HPK1 inhibitors and uses thereof

Also Published As

Publication number Publication date
TW202116751A (zh) 2021-05-01
EP3994133A1 (en) 2022-05-11
EP3994133A4 (en) 2023-11-22
CN116096370A (zh) 2023-05-09
CN114555585A (zh) 2022-05-27
KR20230035061A (ko) 2023-03-10
CA3145973A1 (en) 2021-01-07
MX2022000271A (es) 2022-04-20
MA56462A (fr) 2022-05-11
EP4175951A1 (en) 2023-05-10
WO2021000935A1 (en) 2021-01-07
US20220389037A1 (en) 2022-12-08
AU2021299849A1 (en) 2023-02-23
JP2022538923A (ja) 2022-09-06
IL289612A (en) 2022-03-01
EP4175951B1 (en) 2024-05-01
US20230339896A1 (en) 2023-10-26
JP2023533938A (ja) 2023-08-07
KR20220044495A (ko) 2022-04-08
MX2023000025A (es) 2023-04-04
WO2022002237A1 (en) 2022-01-06
AU2020298649A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
BR112022000064A2 (pt) Inibidores de hpk1 e usos dos mesmos
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
CL2019002204A1 (es) Compuestos inhibidores del vih.
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112021024101A2 (pt) Derivados de tiadiazolila como inibidores de dna polimerase teta
BR112022010383A2 (pt) Compostos tricíclicos substituídos
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112019022512A2 (pt) Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
ECSP18073726A (es) Inhibidores del enlace proteína-proteína de wdr5
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112018067775A2 (pt) inibidores de mcl-1 indol substituído
BR112018002465A2 (pt) derivados de heteroarila como inibidores de parp
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112015032595A8 (pt) inibidores de ido
UY36207A (es) Inhibidores de la syk
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
BR112015023448A2 (pt) compostos e composições para o tratamento de doenças parasíticas
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]